Argus
•
Oct 07, 2026
RCUS: Lowering target price to $23.00
Summary
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Regeneron Pharmaceuticals, Inc.
Oct 30, 2026
•
REGN
Analyst Report: Bristol-Myers Squibb Company
Oct 30, 2026
•
BMY
Analyst Report: Merck & Co., Inc.
Oct 29, 2026
•
MRK
Technical Assessment: Bullish in the Intermediate-Term
Oct 28, 2026
•
MRK, ASML
XNCR: Rating increased to a HOLD
Oct 28, 2026
•
XNCR
